Showing 2751-2760 of 3172 results for "".
- Don't Forget Leprosy: Group Marks 150th Anniversary of Dr. Hansen's Discovery of M. lepraehttps://practicaldermatology.com/news/dont-forget-leprosy-group-marks-150th-anniversary-of-dr-hansens-discovery-of-m-leprae/2461573/The University of Bergen, Norway and Sasakawa Leprosy (Hansen's Disease) Initiative will mark the 150th anniversary of Dr. Gerhard Armauer Hansen's discovery of the leprosy bacillus, M. leprae, in 1873. They plan to hold an
- Game On: Top Derm Video Game Boosts Clinical Decision Making Among Seasoned Doctorshttps://practicaldermatology.com/news/game-on-top-derm-video-game-boosts-clinical-decision-making-among-seasoned-doctors/2461534/Medical video games increase the competence and clinical decision-making of practicing physicians, a new study by Level Ex shows. Substantial research has demonstrated video-game-based medical training’s effectiveness in the short-term. These studies primarily focused on medi
- Study: Psoriasis Does Not Appear to Increase Heart Attack Risk in People with Significant Kidney Diseasehttps://practicaldermatology.com/news/study-psoriasis-does-not-appear-to-increase-heart-attack-risk-in-people-with-significant-kidney-disease/2461387/Studies have suggested that psoriasis is an independent risk factor for heart attack in the general population, but investigators recently found that in people who also have end-stage renal disease, which shares many risk factors with heart disease, it is not. “There are a lot of
- FDA Cracks Down on Three Companies for Selling Unapproved New Drugs for Mole and Skin Tag Removalhttps://practicaldermatology.com/news/fda-cracks-down-on-three-companies-for-selling-unapproved-new-drugs-for-mole-and-skin-tag-removal/2461294/The U.S. Food and Drug Administration issued three warning letters to three companies, including Amazon, for selling unapproved products for removing moles and skin tags, in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act). There are no FDA-appr
- With New Roles for Company Vets, Crown Doubles Down on Commitment to Aestheticshttps://practicaldermatology.com/news/with-new-roles-for-industry-vets-crown-doubles-down-on-commitment-to-aesthetics/2461242/Joe Proctor and Michael McKenna are stepping into new roles at Crown Laboratories. Joe Proctor will transition from General Manager, Aesthetics into the Head of Innovation and Corporate Development for Crown Aesthetics. Mr. Proctor is the founder of Crown
- Murad Joins Forces with Sesame to Offer Skin Care Consults with Dermatologists, Primary Care Doctorshttps://practicaldermatology.com/news/murad-joins-forces-with-sesame-to-offer-skin-care-consults-with-dermatologists-primary-care-doctors/2461194/Murad is partnering with Sesame to introduce skin consultations with board-certified dermatologists and primary care clinicians. <
- Dove Survey: Half of All Girls Say Beauty Advice on Social Media Causes Low Self-Esteemhttps://practicaldermatology.com/news/dove-survey-half-of-all-girls-say-beauty-advice-on-social-media-causes-low-self-esteem/2461172/Two in three girls in the US are spending more than an hour each day on social media. Beauty advice fills their feeds, but unfortunately, it is not all positive. In fact, one of two girls say idealized beauty content on social media causes low self-esteem, according to The D
- Differin Doubles Down on Retinoid Education Week with New Campaign Launchhttps://practicaldermatology.com/news/differin-doubles-down-on-retinoid-education-week-with-new-campaign-launch/2461100/Differin Gel is launching a digital and audio marketing campaign that will culminate in a strategic partnership with Acast Creative and the
- Study Seeks to Evaluate V. Dox Technology's Ability to Improve Healing Following HS Surgical Procedurehttps://practicaldermatology.com/news/study-seeks-to-evaluate-v-dox-technologys-ability-to-improve-healing-following-hs-surgical-procedure/2460958/The first patient has been enrolled in a new study using Vomaris Innovations, Inc.’s s bioelectric antimicrobial wound care technology following surgical treatment for Hidradenitis Suppurativa (HS). When tunnels develop under the skin in HS, a surgical procedure called deroofing i
- First Patient Dosed in Kinnate's Phase 1 trial of KIN-2787 in Patients with BRAF Mutation-Positive Solid Tumorshttps://practicaldermatology.com/news/first-patient-dosed-in-kinnates-phase-1-trial-of-kin-2787-in-patients-with-braf-mutation-positive-solid-tumors/2460894/The first patient has commenced treatment in Kinnate Biopharma Inc.’s Phase 1 KN-8701 trial of its lead RAF product candidate, KIN-2787, a pan-RAF inhibitor being developed for the treatment of patients with melanoma, lung cancer, and other solid tumors. While three kina